Survival Benefit of Radical Prostatectomy in Lymph Node-Positive Patients with Prostate Cancer

European Urology

Volumn 57, Issue 5, 2010, Pages 754-761

  Engel, Jutta ^a   Bastian, Patrick J ^b   Baur, Helmut ^c   Beer, Volker ^d   Chaussy, Christian ^d   Gschwend, Juergen E ^e   Oberneder, Ralph ^f   Rothenberger, Karl H ^g   Stief, Christian G ^b   Hölzel, Dieter ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Hospital Barmherzige Brüder   (Germany)

^d Clinic of Urology   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f Urology Clinic   (Germany)

^g Clinic of Urology   (Germany)

Author keywords

Lymph node; Metastasis; Prostate cancer; Prostatectomy; Survival

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER SURVIVAL; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RELATIVE SURVIVAL; TREATMENT OUTCOME;

AGED; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 77949485478     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.12.034     Document Type: Article

References (30)

1. Heidenreich A., Aus G., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 53 (2008) 68-80
2. Dahm P., Yeung L.L., Chang S.S., and Cookson M.S. A critical review of clinical practice guidelines for the management of clinically localized prostate cancer. J Urol 180 (2008) 451-459 discussion 460
3. Walz J., Gallina A., Saad F., et al. A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. J Clin Oncol 25 (2007) 3576-3581
4. Walsh P.C., DeWeese T.L., and Eisenberger M.A. Clinical practice. Localized prostate cancer. N Engl J Med 357 (2007) 2696-2705
5. Hsu C.-Y., Joniau S., Oyen R., Roskams T., and Van Poppel H. Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. Eur Urol 51 (2007) 121-129 discussion 128-9
6. Freedland S.J., Partin A.W., Humphreys E.B., Mangold L.A., and Walsh P.C. Radical prostatectomy for clinical stage T3a disease. Cancer 109 (2007) 1273-1278
7. Schroder F.H., Kurth K.H., Fossa S.D., et al. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846-a phase III study. J Urol 172 (2004) 923-927
8. Cheng L., Zincke H., Blute M.L., Bergstralh E.J., Scherer B., and Bostwick D.G. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 91 (2001) 66-73
9. Bader P., Burkhard F.C., Markwalder R., and Studer U.E. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?. J Urol 169 (2003) 849-854
10. Schumacher M.C., Burkhard F.C., Thalmann G.N., Fleischmann A., and Studer U.E. Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 54 (2008) 344-352
11. Briganti A., Capitanio U., Chun F.K.-H., et al. Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer. Eur Urol 54 (2008) 794-804
12. Daneshmand S., Quek M.L., Stein J.P., et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 172 (2004) 2252-2255
13. Walsh P.C., Lepor H., and Eggleston J.C. Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate 4 (1983) 473-485
14. Walsh P.C., and Mostwin J.L. Radical prostatectomy and cystoprostatectomy with preservation of potency. Results using a new nerve-sparing technique. Br J Urol 56 (1984) 694-697
15. Heidenreich A. Radical prostatectomy in 2007: oncologic control and preservation of functional integrity. Eur Urol 53 (2008) 877-879
16. Fleischmann A., Schobinger S., Markwalder R., et al. Prognostic factors in lymph node metastases of prostatic cancer patients: the size of the metastases but not extranodal extension independently predicts survival. Histopathology 53 (2008) 468-475
17. Fleischmann A., Schobinger S., Schumacher M., Thalmann G.N., and Studer U.E. Survival in surgically treated, nodal positive prostate cancer patients is predicted by histopathological characteristics of the primary tumor and its lymph node metastases. Prostate 69 (2009) 352-362
18. Boormans J.L., Wildhagen M.F., Bangma C.H., Verhagen P.C., and van Leenders G.J. Histopathological characteristics of lymph node metastases predict cancer-specific survival in node-positive prostate cancer. BJU Int 102 (2008) 1589-1593
19. Heidenreich A., Ohlmann C.H., and Polyakov S. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol 52 (2007) 29-37
20. Briganti A., Blute M.L., Eastham J.H., et al. Pelvic lymph node dissection in prostate cancer. Eur Urol 55 (2009) 1251-1265
21. Schlomm T., Borgermann C., Heinzer H., Rubben H., Huland H., and Graefen M. Role of lymph node dissection in prostate cancer [in German]. Urologe A 48 (2009) 37-45
22. Gervasoni Jr. J.E., Sbayi S., and Cady B. Role of lymphadenectomy in surgical treatment of solid tumors: an update on the clinical data. Ann Surg Oncol 14 (2007) 2443-2462
23. Nguyen D.X., Bos P.D., and Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 9 (2009) 274-284
24. Boorjian S.A., Thompson R.H., Siddiqui S., et al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol 178 (2007) 864-870 discussion 870-1
25. Messing E.M., Manola J., Yao J., et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7 (2006) 472-479
26. Frohmuller H.G.W., Theiss M., Manseck A., and Wirth M.P. Survival and quality of life of patients with stage D1 (T1-3 pN1-2 M0) prostate cancer: radical prostatectomy plus androgen deprivation versus androgen deprivation alone. Eur Urol 27 (1995) 202-206
27. Wong Y.N., Freedland S., Egleston B., Hudes G., Schwartz J.S., and Armstrong K. Role of androgen deprivation therapy for node-positive prostate cancer. J Clin Oncol 27 (2009) 100-105
28. Briganti A., Karnes J.R., Da Pozzo L.F., et al. Two positive nodes represent a significant cut-off value for cancer-specific survival in patients with node-positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 55 (2009) 261-270
29. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433-439
30. Da Pozzo L.F., Cozzarini C., Briganti A., et al. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur Urol 55 (2009) 1003-1011